Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available.
BioArctic AB’s partner Eisai announced that Leqembi® has been included in China’s ‘Commercial Insurance Innovative Drug List,’ a significant step towards expanding access to early Alzheimer’s Disease treatment in China. This inclusion is expected to bridge the gap between basic reimbursement systems and innovative medicines, potentially impacting the company’s market presence and offering new opportunities for stakeholders.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company is known for inventing Leqembi® (lecanemab), a drug that slows the progression of Alzheimer’s disease. BioArctic collaborates with Eisai for global regulatory interactions and commercialization. The company also has a research portfolio targeting Parkinson’s disease, ALS, and other Alzheimer’s disease projects, utilizing its proprietary BrainTransporter™ technology.
Average Trading Volume: 188,468
Technical Sentiment Signal: Buy
Current Market Cap: SEK27.26B
For detailed information about BIOA.B stock, go to TipRanks’ Stock Analysis page.